Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Learn how real-world data (RWD) can be utilized in clinical trials to create more diverse control arms and expedite the process of bringing therapies to market. The FDA's considerations for sponsors using RWD in external control arms are essential for understanding the benefits of this approach.The Centers for Medicare and Medicaid Services (CMS) have introduced a new pathway, Transitional Coverage for Emerging Technologies, which will evaluate five medical device candidates annually for national coverage. Various acquisitions and partnerships within the healthcare industry are shaping the landscape, including Zimmer's acquisition of OrthoGrid and Abbott collaborating with Medtronic on diabetes technology.Updates in the healthcare industry encompass a range of topics, from Walgreens considering a full sale of VillageMD to the increasing uninsured rate. Leveraging technology such as AI, virtual reality, and robotics is becoming more prevalent in healthcare to enhance decision-making and patient engagement.Eli Lilly's successful quarter and Novavax's revenue miss highlight the diverse outcomes seen in the pharmaceutical industry. The merger of Recursion and Exscientia signifies a step forward in drug discovery using AI, while companies like Apellis and Madrigal continue to make strides with new drug launches.Eli Lilly's positive performance in the second quarter, along with Novavax's challenges, demonstrate the dynamic nature of the pharmaceutical market. Merck's halt of a phase III trial and Novartis' FDA approval for Fabhalta further showcase the evolving landscape of drug development and approvals.The top-selling drugs in 2024 from leading pharmaceutical companies like Eli Lilly and Roche offer insights into current trends in the industry. With a focus on diversity, commercialization strategies, and oncology research, the pharmaceutical sector continues to evolve to meet changing demands.